Skip to main content

Table 4 Univariate and multivariate analysis of recurrence-free survival (RFS) for breast cancer patients who received adjuvant CIK cell immunotherapy

From: PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer

Variables Univariate analysis Multivariate analysis
HR 95% CI p value HR 95% CI p value
Age (<  50 vs. ≥ 50) 1.084 0.723–1.359 0.689    
Tumor size (<  20 vs. ≥ 20) (mm) 2.970 1.668–4.515 < 0.001* 1.903 0.311–3.783 0.546
TNM stage (I-II vs. III) 1.803 1.389–3.019 0.020* 1.695 1.119–2.513 0.028*
Histological differentiation (I-II vs. III) 1.015 0.801–1.763 0.812    
Positive lymph node ratio (< 0.21 vs. ≥ 0.21) 1.997 0.873–3.072 0.065    
ER (pos vs. neg) 0.582 0.312–1.878 0.475    
PR (pos vs. neg) 0.718 0.453–2.145 0.327    
Herb2 (pos vs. neg) 1.510 1.108–2.918 0.035* 1.792 0.589–2.807 0.699
PD-L1 expression (pos vs. neg) 0.596 0.214–0.963 < 0.001* 0.604 0.437–0.895 < 0.001*
TNBC (yes vs. no) 1.958 0.698–3.217 0.760    
  1. HR Hazard ratio, CI confidence interval; *Statistically significant, p < 0.05